Keyword: ABPI

New ads from Britain's pharma trade group talk up the country's process for pricing new drugs—and pharma's role within it.

In a new five-year deal with the National Health Service, pharma will limit its sales growth on branded drugs to 2% each year.

NICE’s loss is the pharma industry’s gain in the U.K. as Carole Longson, a respected authority in drug value assessment, has joined ABPI.

Pharmaceutical companies took a hard stance against new cost-management strategies in England but have now fallen short.

The pharma industry is challenging a U.K. clampdown for meds projected to cost more than £20 million per year.

Astellas’ U.K. unit was already suspended from the Association of the British Pharmaceutical Industry. And now, that suspension has been extended.

​​​​​​​Patients in the U.K. face yet another barrier to access with reports the country is considering drug rationing.

The U.K.’s promotional police cracked down on biosimilar marketing this week, citing Pfizer’s Hospira unit and Napp Pharmaceuticals for code violations at meetings they hosted for healthcare providers.

Worried that GlaxoSmithKline or AstraZeneca might pull up their U.K. roots in the wake of Brexit? Rest easy. Both companies are set to reassure the world this week that they’re staying put.

Will pharma’s Brexit fears come to pass? The U.K.’s life sciences minister, George Freeman, isn't ruling out the idea of splitting Britain’s drug regulation away from the European Medicines Agency.